Strategic collaboration combines germline genetic testing, next-generation tumor sequencing and world-class testing capabilities to elevate global precision oncology care
SALT LAKE CITY, March 02, 2021 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a new strategic precision oncology collaboration with Intermountain Precision Genomics, a service of Intermountain Healthcare. This collaboration creates a comprehensive germline genetic testing and somatic tumor offering that combines Myriad’s advanced hereditary cancer and companion diagnostic tests with Intermountain Precision Genomics’ world-class laboratory services, utilizing the TheraMap® test—powered by the TruSight™ Oncology 500 (TSO 500) next-generation sequencing test from Illumina, Inc. (NASDAQ: ILMN).
TSO 500 is rapidly becoming a standard in oncology. Through the offering, oncologists will obtain a complete genetic analysis in one, easy-to-interpret report, enabling them to leverage the benefits of comprehensive genomic profiling.
“As cancer treatment continues to evolve, most oncologists seek both germline and somatic tumor testing results to best guide treatment decisions. Advancing precision oncology requires strong collaboration between forward-looking organizations across the healthcare ecosystem. This alliance with Intermountain Precision Genomics is an example of our drive to improve health outcomes for patients with cancer and expand innovative treatment options for the healthcare providers who care for them,” said Paul J. Diaz, president and CEO, Myriad Genetics. “We are successfully merging the power of companion diagnostics, next-generation tumor sequencing, and world-class testing services to help raise the global standard of care in precision oncology.”
“As a physician, I’m excited to make this comprehensive offering available to more patients,” said Lincoln Nadauld, MD, PhD, oncologist and vice president and chief of precision health and academics at Intermountain Healthcare. “This partnership allows us to make a tremendous impact by providing the best that precision cancer care has to offer.”
Strategic Partnership with Intermountain Precision Genomics
Intermountain Precision Genomics is a nationally recognized program focused on building partnerships to accelerate the field even further. The new, comprehensive offering – set to be available in the second half of 2021 – will utilize germline genetic testing with the Myriad myRisk® Hereditary Cancer test, and somatic tumor profiling with Myriad myChoice® CDx. Intermountain Precision Genomics will perform tumor profiling and tissue analysis using its TheraMap® test that is powered by Illumina’s TSO 500 assay.
Myriad myChoice CDx is widely supported by private insurance payers. Both myChoice CDx and TheraMap are covered by Medicare.
Author / source: Myriad / https://myriad.com/investors/news-release/news-release-detail/?newsItemId=21916
